Back to top

Image: Bigstock

Opko Health (OPK) Catches Eye: Stock Adds 5.6% in Session

Read MoreHide Full Article

Opko Health, Inc. (OPK - Free Report) was a big mover last session, as its shares rose almost 6% on the day. The upside was driven by the FDA approval of Rayaldee for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. This also led to far more shares changing hands than in a normal session. Yesterday’s rally reverses the downtrend for the company since Jun 2, as the stock is now down almost 8%.

Over the last 30 days, the company witnessed one positive and one negative estimate revision. Meanwhile, the Zacks Consensus Estimate moved higher, suggesting solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

Opko Health has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the med instruments space is CryoLife Inc. , sporting a Zacks Rank #1 (Strong Buy).

Is OPK going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 DaysClick to get this free report >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


OPKO Health, Inc. (OPK) - free report >>

Published in